ENTITY
Samsung Biologics

Samsung Biologics (207940 KS)

441
Analysis
Health Care • South Korea
Samsung Biologics Co.,Ltd. manufactures bio-healthcare products. The Company develops, refines, and distributes biopharmaceutical products.
more
bullish•Samsung Biologics
•20 Nov 2025 22:52

Samsung Bioepis Holdings and Samsung Biologics to Start Trading on 24 November

​Samsung Biologics and Samsung Bioepis Holdings will start trading on 24 November with positive outlook due to improving operating leverage and...

Logo
525 Views
Share
bullish•Samsung Biologics
•31 Oct 2025 19:56•Broker

Samsung Biologics (207940 KS/Buy)Spin-Off Likely to Unlock Additional Value

We raise our target price for Samsung Biologics to W1,600,000 (from W1,400,000), which is based on the sum of the values of the CDMO business...

Logo
515 Views
Share
bullish•Samsung Biologics
•30 Oct 2025 08:30

Samsung Biologics (207940 KS): Momentum Accelerates in 3Q; Solid Order Book; Reaffirms FY Guidance

​Samsung Biologics reports strong revenue and profit growth in 3Q25, secures new contracts with global pharmaceutical partners, and aims to achieve...

Logo
509 Views
Share
bearish•Quantitative Analysis
•22 Dec 2025 07:05

KRX Foreign Holding Weekly (Dec 19th): HD HYUNDAI HEAVY INDUSTRIES, Samsung Electronics

We analyzed KRX foreign holding data for the past week and highlighted foreign holding changes in HD HYUNDAI HEAVY INDUSTRIES, Samsung Electronics,...

Logo
123 Views
Share
bullish•Samsung Biologics
•22 Aug 2025 20:53

Biologics Spinco Filing: Posts Far More Aggressive Post-Listing Share Swap Lock-Up Than Expected

This post covers Samsung Biologics’ spinco filing, which imposes a far-tougher-than-expected post-listing share swap lock-up.

Logo
666 Views
Share
x